AMPICLOX LC

Main information

  • Trade name:
  • AMPICLOX L.C. LACTATING COW INTRAMAMMARY ANTIBIOTIC INFUSION
  • Pharmaceutical form:
  • MISC. INTRA MAMMARY
  • Units in package:
  • 20x3g Syringes
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • AMPICLOX L.C. LACTATING COW INTRAMAMMARY ANTIBIOTIC INFUSION
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CATTLE LACTATING | BOVINE
  • Therapeutic area:
  • antibiotic
  • Therapeutic indications:
  • CORYNEBACTERIUM PYOGENES | ESCHERICHIA COLI (E. COLI) | STAPHYLOCOCCI | STREPTOCOCCI | INCLUDING B-LACTAMASE PRODUCIN
  • Product summary:
  • For the treatment of mastitis in lactating cows caused by organisms sensitive to Ampicillin and Cloxacillin.Milk taken from cows with 72 hours of treatment also must not be fed to bobby calves.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 35849/1208
  • Authorization date:
  • 22-04-2009
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

TRADE ADVICE

EXPORT SLAUGHTER INTERVAL (ESI):

This product does not have an ESI established.

For advice on the ESI contact Jurox Pty Ltd on 1800 023 312 before using this product.

FIRST AID: If poisoning occurs, contact a doctor or Poisons Information Centre,

phone 13 11 26.

Dispose of empty syringes by wrapping with paper and putting in the garbage.

STORE below 25

C (Air Conditioning).

Made in Australia by

Jurox Pty Ltd

85 Gardiner Road, Rutherford, NSW 2320

Australia 1800 023 312

Ampiclox L.C.

LACTATING COW

Ampiclox L.C.

LACTATING COW

Ampiclox L.C.

LACTATING COW

Ampiclox L.C.

LACTATING COW

PRESCRIPTION ANIMAL REMEDY

KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

Each 3g syringe contains:

75mg AMPICILLIN (as Sodium Salt)

200mg CLOXACILLIN (as Sodium Salt)

For treatment of mastitis in lactating cows caused by

organisms sensitive to Ampicillin and Cloxacillin.

20 Syringes each 3g

DIRECTIONS FOR USE

READ ENCLOSED LEAFLET BEFORE USING THIS PRODUCT

DOSE: Apply one syringe every 12 hours for 3 treatments per infected quarter.

ADMINISTRATION: After milking, clean and disinfect the teat with an

approved teat disinfectant, insert the nozzle into the teat canal and apply

gentle and continuous pressure on the plunger until all the suspension is

expressed. Wear sanitized rubber gloves when applying. Dip all teats after

infusing, in an approved teat disinfectant. The treated quarter(s) should be

milked out at the next milking and milk withheld from general collection.

For advice on feeding calves with milk taken during the withholding period,

contact your prescribing Veterinarian.

WITHHOLDING PERIODS:

MILK: Milk taken from cows within 72 hours (6 milkings) following treatment

MUST NOT BE USED for human consumption or processing, or fed to

bobby calves.

MEAT: DO NOT USE less than 30 days before slaughter for human consumption.

Exp.

APVMA Approval No. 35849/20Syr/1208

405517

APVMA file name: 35849_46326_20x3g_primary_MPL_V01.pdf

Dimensions: primary pack = 508mm (wide) x 316mm (high)

Scale: 75% on A3

Date: 26 – 3 – 2009

APPROVED

LABEL

Info

pest

Verified

APVMA FILE: 35849_46326_3g_immediate_MPL_V01.pdf

Dimensions: label = 40mm (wide) x 57mm (high)

Scale: 100% of A4

Date: 13 March 2009

Each 3g syringe

contains: 75mg

AMPICILLIN (as Sodium Salt)

200mg CLOXACILLIN (as Sodium Salt)

READ ENCLOSED LEAFLET BEFORE USE

DIRECTIONS: Apply one syringe

every 12 hours for 3 treatments

per infected quarter

WITHHOLDING PERIODS

MILK: 72 hours MEAT: 30 days

Store below 25°C (Air Conditioning).

I

n

t

r

a

m

a

m

m

a

r

y

A

n

t

i

b

i

o

t

i

c

I

n

f

u

s

i

o

n

LACTATING COW

Ampiclox

L

.

C

.

PRESCRIPTION ANIMAL REMEDY

KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

Exp.

85 Gardiner Road,

Rutherford, NSW 2320

405508 APVMA No. 35849/3g/1208

APPROVED

LABEL

PRESCRIPTION ANIMAL REMEDY

KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

AMPICLOX L.C.

LACTATING COW

Intramammary Antibiotic Infusion

PRODUCT SUMMARY

Ampiclox L.C. Lactating Cow Intramammary Antibiotic Infusion is

a broad spectrum antibiotic preparation and indicated for the early

treatment

bovine

mastitis

where

sensitive

organisms

present. It is bactericidal to penicillin resistant and sensitive

Staphylococci, Streptococci and Corynebacterium pyogenes as

well as Escherichia coli and other Gram-negative bacteria.

DESCRIPTION

Ampiclox

L.C.

stable

suspension

containing

75mg

ampicillin and 200mg of cloxacillin as the sodium salts in a quick

release base.

The active constituents have the following chemical names:

(a) Cloxacillin Sodium i.e. sodium (6R)-6-[3-(2-chlorophenyl)-5-

methylisoxazole-4-caboxamido] penicillinate monohydrate.

Ampicillin

sodium

i.e.

(6R)-6-(α D-Phenylglycylamino)

sodium penicillanate.

Ampicillin and cloxacillin are derived from the penicillin nucleus,

6-aminopenicillanic acid.

Ampiclox

L.C.

presented

syringe

suitable

intramammary infusion and is designed for the treatment of

clinical mastitis under veterinary supervision.

ACTION

Ampiclox L.C. is a broad spectrum antibiotic and is bactericidal at

the concentrations achieved in the udder. It is non-irritant in the

udder tissues.

Ampiclox L.C. is active against Gram-positive and Gram-negative

bacteria associated with mastitis. It is highly effective against

Streptococcus

agalactiae

other

streptococcal

species,

penicillin resistant and sensitive Staphylococci, Corynebacterium

pyogenes,

Escherichia

coli

some

other

Gram-negative

bacteria.

It is therefore active against all major causative organisms of

mastitis.

INDICATIONS

Ampiclox L.C. is indicated for the treatment of mastitis in lactating

cows caused by organisms sensitive to ampicillin and cloxacillin.

It is particularly recommended where the causative organisms

have not been identified and where E.coli are known or suspected

to be involved. The best results will be obtained when treatment is

commenced at the first signs of infection, before there is too much

tissue damage or abscess formation.

DOSE

Apply one syringe every 12 hours for 3 treatments per affected

quarter.

ADMINISTRATION

After milking, clean and disinfect the teat with an approved teat

disinfectant, insert the nozzle into the teat canal and apply gentle

and continuous pressure on the plunger until all the suspension is

expressed. Wear sanitised rubber gloves when applying. Dip all

teats after infusing in an approved teat disinfectant.

The treated quarter(s) should be milked out at the next normal

milking and milk withheld from the general collection. For advice

on feeding calves with milk taken during the withholding period,

contact your prescribing veterinarian.

WITHHOLDING PERIODS

MILK: Milk taken from cows within 72 hours (6 milkings)

following

treatment

MUST

NOT

BE

USED

for

human

consumption or processing, or fed to bobby calves.

MEAT: DO NOT USE less than 30 days before slaughter for

human consumption.

TRADE ADVICE

EXPORT SLAUGHTER INTERVAL (ESI): This product does not

have an ESI established. For advice on the ESI contact Jurox Pty

Ltd on 1800 023 312 before using this product.

FIRST AID

If poisoning occurs, contact a doctor or Poisons Information

Centre, phone 13 11 26.

DISPOSAL

Dispose of empty syringes by wrapping with paper and putting in

garbage.

STORAGE

Store below 25°C (Air Conditioning).

APVMA Approval No. 35849/1208

AVAILABILITY

Ampiclox L.C. is supplied in cartons of 20 syringes.

DRY COW THERAPY

Selective dry cow therapy is recommended as a valuable aid in the

control of mastitis. Contact your consulting veterinarian. Ampiclox

Intramammary

Antibiotic

Infusion

formulated

specifically for this purpose, and is available in cartons of 20

syringes and buckets of 120 syringes.

405513

Made in Australia by:

Jurox Pty Ltd

85 Gardiner Road,

Rutherford NSW 2320

Infoline 1800 023 312

Overall size 74mm x 105mm is 100% size 74mm x 105mm folded to 105mm x 36mm

APVMA file name: 35849 _ 46326 _ leaflet _ MPL _ VO1.pdf

Dimensions: leaflet = 74mm x 105mm per side

Scale: 100% on A4

Date: 26 – 3 – 2009

74mm

74mm

105mm

105mm

APPROVED

LABEL

19-12-2018

Safety and efficacy of vitamin B2 (riboflavin 5′‐phosphate ester monosodium salt) for all animal species when used in water for drinking

Safety and efficacy of vitamin B2 (riboflavin 5′‐phosphate ester monosodium salt) for all animal species when used in water for drinking

Published on: Tue, 18 Dec 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on vitamin B2 in the form of riboflavin 5′‐phosphate ester monosodium salt as an additive for all animal species for use in water for drinking. The additive under assessment is obtained from ■■■■■ a source of riboflavin produced by Ashbya gossypii. No information was provided on the identity and character...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-12-2018

Moonstruck Chocolate Co. Issues Allergy Alert On Undeclared Hazelnuts In 4 Oz. Sea Salt Caramels Tumbled In Milk Chocolate

Moonstruck Chocolate Co. Issues Allergy Alert On Undeclared Hazelnuts In 4 Oz. Sea Salt Caramels Tumbled In Milk Chocolate

Moonstruck Chocolate Company of Portland, Oregon is recalling 600/4 oz. bags of Sea Salt Caramels Tumbled In Milk Chocolate, because it may contain undeclared hazelnuts. People who have an allergy or severe sensitivity to hazelnuts run the risk of a serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

1-12-2018

Tres Hermanos Bakery Issues Allergy Alert on Undeclared Milk in Telera and Bolillo Breads

Tres Hermanos Bakery Issues Allergy Alert on Undeclared Milk in Telera and Bolillo Breads

Tres Hermanos Bakery of Wyoming, MI is recalling its white Telera and Bolillo Mexican salt breads because they may contain undeclared milk. People who have allergies to milk run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

9-11-2018

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of polyacrylic acid, sodium salt, cross‐linked, FCM substance No 1015, which is intended to be used as a liquid absorber in the packaging of fresh or frozen foods such as meat, poultry and seafood as well as fresh fruits and vegetables. Specific migration tests were not performed due to the high absorption of liquids by the substance. The Panel noted that if polya...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

2-11-2018

Frito-Lay Issues Allergy Alert on Undeclared Milk In Select Smartfood Delight Sea Salt Flavored Popcorn

Frito-Lay Issues Allergy Alert on Undeclared Milk In Select Smartfood Delight Sea Salt Flavored Popcorn

Frito-Lay announced a voluntary recall of select 1/2 oz. bags of Smartfood Delight Sea Salt Flavored popcorn because they were inadvertently filled with cheese flavored tortilla chips that contain undeclared milk ingredients. The recalled bags were sold only in the two variety packs listed below.

FDA - U.S. Food and Drug Administration

2-11-2018

Barcelona Nut Company Recalls Roasted and Salted in Shell Pistachios Because of Possible Health Risk

Barcelona Nut Company Recalls Roasted and Salted in Shell Pistachios Because of Possible Health Risk

Barcelona Nut Company of Baltimore, Maryland is recalling 239 cases of roasted and salted in shell pistachios, because it has the potential to be contaminated with Salmonella, an organism that can cause serious and sometimes-fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain.

FDA - U.S. Food and Drug Administration

29-10-2018

Maribel’s Sweets Inc. Allergy Alert on Undeclared Milk Allergens in Chocolate Bars

Maribel’s Sweets Inc. Allergy Alert on Undeclared Milk Allergens in Chocolate Bars

Maribel’s Sweets Inc. of Brooklyn, NY is recalling its 2.82oz MarieBelle Japanese Matcha Japanese Green Tea and White Chocolate Bar, container code 101619, Cacao Market by MarieBelle Rosemary Truffle Salt 60% Dark Chocolate Bar, all container codes, and the Cacao Market by MarieBelle Orange Peels 60% Dark Chocolate Bar, all container codes, because they may contain undeclared milk allergens. Consumers who are allergic to milk allergens may run the risk of serious or life-threatening allergic reactions if...

FDA - U.S. Food and Drug Administration

8-9-2018

Steve’s Real Food Voluntarily Recalls One Lot of Turducken Recipe, One Lot of Quest Emu, and One Lot of Quest Beef Due to Possible Salmonella and L. Mono Contamination

Steve’s Real Food Voluntarily Recalls One Lot of Turducken Recipe, One Lot of Quest Emu, and One Lot of Quest Beef Due to Possible Salmonella and L. Mono Contamination

Steve’s Real Food of Salt Lake City, Utah is voluntarily recalling one lot of 5lb Turducken Recipe, one lot of 2lb Quest Emu Diet, and one lot of 2lb Quest Beef Diet, due to their possible Salmonella and/or L. mono contamination.

FDA - U.S. Food and Drug Administration

15-8-2018

Salt & Straw Voluntarily Recalls Certain Lots of Chocolate Gooey Brownie Ice Cream Pints Due to Possible Undeclared Peanuts

Salt & Straw Voluntarily Recalls Certain Lots of Chocolate Gooey Brownie Ice Cream Pints Due to Possible Undeclared Peanuts

Salt & Straw Ice Cream is voluntarily recalling a limited number of its Chocolate Gooey Brownie pints because it may contain undeclared peanuts. People who have an allergy or severe sensitivity to peanuts run the risk of a serious or life threatening allergic reaction if they consume this product. The product is safe to consume unless you have a peanut allergy or sensitivity. No illnesses have been reported to date in connection with this problem.

FDA - U.S. Food and Drug Administration

4-5-2018

Maya Distribution, LLC Recalls Dragon Label Kratom Because Of Possible Salmonella Contamination

Maya Distribution, LLC Recalls Dragon Label Kratom Because Of Possible Salmonella Contamination

Maya Distribution, LLC of South Salt Lake City, Utah is voluntarily recalling Dragon Kratom labeled bottles and sealed packages of encapsulated and raw powder product because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. 

FDA - U.S. Food and Drug Administration

20-12-2018


Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-c

Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-c

Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt, Treatment of beta-thalassaemia intermedia and major, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

19-12-2018


Orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt, Treatment of acute myeloid leukaemia, 24/08/2018, Positive

Orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt, Treatment of acute myeloid leukaemia, 24/08/2018, Positive

Orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt, Treatment of acute myeloid leukaemia, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

10-12-2018

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (Active substance: (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt) - Transfer of orphan designation - Commission Decision (2018)8636 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002385

Europe -DG Health and Food Safety

26-11-2018


Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Europe - EMA - European Medicines Agency

28-8-2018

EU/3/18/2057 (Pharm Research Associates (UK) Limited)

EU/3/18/2057 (Pharm Research Associates (UK) Limited)

EU/3/18/2057 (Active substance: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt) - Orphan designation - Commission Decision (2018)5729 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/051/18

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt) - Transfer of orphan designation - Commission Decision (2018)3797 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/16/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt) - Transfer of orphan designation - Commission Decision (2018)3798 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/166/12/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3802 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/152/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3801 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/020/11/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3799 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/11/T/03

Europe -DG Health and Food Safety